How do antibody-drug conjugates (ADCs) target tumors while minimizing off-target effects? Learn how Quantitative Whole-body Autoradiography (QWBA) helps optimize ADC development in our latest blog. #ADC #DMPK #ADME #QWBA
WuXi AppTec Laboratory Testing Division - DMPK Services
Pharmaceutical Manufacturing
Cranbury, New Jersey 73 followers
About us
DMPK Services—part of WuXi AppTec's Laboratory Testing Division—provides expert preclinical drug development testing for more than 90% of the world’s largest pharmaceutical companies, as well as a diverse, global client base of 1,000+ small and medium-sized companies within biopharma, non-profit, and academic sectors. Whether you’re in the early stages of discovery or preparing to submit a New Drug Application (NDA), we offer comprehensive services, customized studies, high standards and quality, and fast turnaround that help advance you further, faster—all backed by years of extensive experience and expertise. Our solutions serve a wide range of needs across discovery screening, preclinical development, and clinical drug metabolism and pharmacokinetics. This includes support for a diverse range of molecules and compounds, including new modalities such as oligonucleotides, antibody-drug conjugates, peptides, peptide-drug conjugates, and proteolysis targeting chimeras. We also offer a variety of study packages to help you accelerate development and save cost, from Drug-Drug Interaction (DDI) to Biotransformation and In Vivo Absorption, Distribution, Metabolism and Excretion (ADME) to Investigational New Drug (IND)-Enabling. With locations in the United States and China, WuXi AppTec DMPK is a true global partner for DMPK studies and deeply invested in the success of our clients, through drug development, regulatory submission and beyond.
- Website
-
labtesting.wuxiapptec.com/dmpk-services
External link for WuXi AppTec Laboratory Testing Division - DMPK Services
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Cranbury, New Jersey
- Founded
- 2000
- Specialties
- Metabolic Stability Studies, IND-Enabling ADME, NDA-Enabling ADME, Rodent Pharmacokinetics, Large Animal Pharmacokinetics, Non-GLP Bioanalysis, Metabolite Profiling and Identification, Mass Balance , Tissue Distribution, Whole Body Autoradiography (QWBA), Human Radiolabel-AME Studies, Drug-Drug Interactions, Drug Metabolism and Pharmacokinetics, Oligonucleotides, Antibodies, Peptides, Small Molecules, and Biologics
Updates
-
How does in vitro ADME testing work for your drug discovery and early development, and why is it so crucial? Find out in our short guide: A Guide to In Vitro ADME Testing in Drug Development. #InVitro #ADME #Preclinical #DrugDevelopment
A Guide to In Vitro ADME Testing in Drug Development
WuXi AppTec Laboratory Testing Division - DMPK Services on LinkedIn
-
Drug–melanin binding can significantly influence drug retention, pharmacokinetics, and safety in melanin-rich tissues. We have developed efficient in vitro methods to study these interactions, providing critical insights to advance safer, more effective therapeutics. Read our latest blog to learn more about drug–melanin binding studies. #DrugDevelopment #Pharmacokinetics #Ophthalmology #Innovation #DMPK #ADME
Exploring Drug Binding to Melanin: Impacts and Methods
WuXi AppTec Laboratory Testing Division - DMPK Services on LinkedIn
-
Understanding time-dependent inhibition (TDI) is essential to predicting and mitigating drug-drug interaction (DDI) risks. Our in vitro ADME team at WuXi AppTec combines advanced IC50 and AUC shift approaches to provide accurate TDI assessments, supporting safer and more effective drug development. Learn more about our expertise in evaluating TDI. #DrugDevelopment #PharmaScience #DrugInteractions #CYP450 #PreclinicalResearch #Pharmaceuticals #ADME #DMPK
Understanding the Critical Role of Time-Dependent Inhibition (TDI) in Drug-Drug Interaction Risk
WuXi AppTec Laboratory Testing Division - DMPK Services on LinkedIn
-
Excited to share our advancements of quantitative analysis of oligonucleotide. With HELISA and MSD® ECL ligand binding assays, we’re enhancing sensitivity and throughput in preclinical PK studies, overcoming challenges like metabolite interference, and ensuring regulatory compliance for oligonucleotide quantification. #OligonucleotideResearch #Bioanalysis #DrugDevelopment #Pharmacokinetics #DMPK
How to Use Ligand Binding Assays (LBA) for DMPK Quantitative Analysis of Oligonucleotide
WuXi AppTec Laboratory Testing Division - DMPK Services on LinkedIn
-
Radionuclide drug conjugates (RDCs) offer targeted cancer treatment and diagnostic capabilities with significantly reduced side effects. By overcoming drug resistance and combining diagnostics with therapy, RDCs are driving advancements in modern oncology. Read this article to learn more. #Oncology #RDCs #PrecisionMedicine #DMPK #DrugDevelopment
How Radionuclide Drug Conjugates are Transforming Cancer Treatment
WuXi AppTec Laboratory Testing Division - DMPK Services on LinkedIn
-
Peptide drugs offer high target affinity and specificity but are often challenged by low bioavailability and short circulation times, which can limit their therapeutic effectiveness. Optimizing DMPK properties is key to unlocking their full potential. Join WuXi AppTec and AAPS for an exclusive webinar on peptide DMPK optimization strategies. Learn how our in vitro models, customized sample processing, and expert insights can elevate your peptide drug development from early screening to IND submission. 📅 Date: November 6, 2024 🕒 Time: 11:15 AM - 11:45 AM EST 🔗 Register here: https://lnkd.in/g_DJgCkU (free to everyone, but need to register a free account at AAPS) #PeptideDrugs #DMPK #PharmaResearch #DrugDevelopment #Bioavailability #PharmaceuticalScience #INDSubmission
-
-
If you plan to attend AAPS, please join the Partner Presentation session on "Integrated Bioanalysis and Biotransformation Strategies for Antibody-Drug Conjugates" on Monday, October 21, 2024 from 11:00 AM – 12:00 PM MT at 360 Stage #4, Exhibit Hall. Presented by: Li Qu, Ph.D., Deputy Director, Non-GLP Bioanalysis, WuXi AppTec Peng Li, Ph.D., Senior Scientist, MetID, WuXi AppTec Key topics include: Pharmacokinetic evaluation of ADCs Metabolite profiling and Drug-to-Antibody Ratio (DAR) analysis Strategies for overcoming challenges in ADC development Looking forward to seeing you there! #AAPS2024 #Bioanalysis #ADCs #DrugDevelopment #ADCTherapies #PharmSci360 #DMPK
-
-
Struggling with the bioavailability of poorly water-soluble compounds in drug development? Our latest blog explores key strategies, including solvent selection and particle size reduction, used by WuXi AppTec's DMPK team to optimize preclinical pharmacokinetic studies. Discover how these approaches can improve absorption and accelerate your drug development process!
How to Improve the Bioavailability of Poorly Water-Soluble Compounds?
WuXi AppTec Laboratory Testing Division - DMPK Services on LinkedIn
-
If you plan to attend AAPS, please join the Partner Presentation session on "Integrated Bioanalysis and Biotransformation Strategies for Antibody-Drug Conjugates" on Monday, October 21, 2024 from 11:00 AM – 12:00 PM MT at 360 Stage #4, Exhibit Hall. Presented by: Li Qu, Ph.D., Deputy Director, Non-GLP Bioanalysis, WuXi AppTec Peng Li, Ph.D., Senior Scientist, MetID, WuXi AppTec Key topics include: Pharmacokinetic evaluation of ADCs Metabolite profiling and Drug-to-Antibody Ratio (DAR) analysis Strategies for overcoming challenges in ADC development Looking forward to seeing you there! #AAPS2024 #Bioanalysis #ADCs #DrugDevelopment #ADCTherapies #PharmSci360 #DMPK
-